These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2524303)

  • 21. [Medroxyprogesterone acetate (MPA) in the treatment of advanced breast cancer].
    Izuo M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2604-11. PubMed ID: 2956928
    [No Abstract]   [Full Text] [Related]  

  • 22. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
    Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
    Dryzhak VI
    Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).
    Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Mazy V
    Acta Oncol; 1989; 28(2):237-40. PubMed ID: 2525397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer].
    Doihara H; Takashima S; Saeki H; Takiyama W; Kurita A; Soga H; Tanada M; Yokoyama N; Moriwaki S
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2057-62. PubMed ID: 2145805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of pharmacokinetics in the clinical treatment of metastases.
    Pannuti F; Camaggi CM; Strocchi E
    Adv Exp Med Biol; 1988; 233():443-52. PubMed ID: 2975917
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].
    Bastert G; Michel RT
    Med Welt; 1983 Mar; 34(12):378-82. PubMed ID: 6222235
    [No Abstract]   [Full Text] [Related]  

  • 31. [Depo-Provera--antineoplastic agents which is also a contraceptive].
    Tylleskär J
    Jordemodern; 1988 Mar; 101(3):55-8. PubMed ID: 2967271
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
    Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
    Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
    [No Abstract]   [Full Text] [Related]  

  • 33. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.
    Blossey HC; Bartsch HH; Kanne D; Koebberling J; Nagel GA
    Cancer Chemother Pharmacol; 1982; 8(1):77-81. PubMed ID: 6212156
    [No Abstract]   [Full Text] [Related]  

  • 34. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of oral medroxyprogesterone acetate in advanced germ cell tumors.
    Cavalli F; Klepp O; Hansen H; Rozencweig M
    Cancer Treat Rep; 1983 Oct; 67(10):953-4. PubMed ID: 6313188
    [No Abstract]   [Full Text] [Related]  

  • 36. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
    Lorenz I; Mechl Z
    Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
    Kjaer M
    Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
    [No Abstract]   [Full Text] [Related]  

  • 38. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the results of treatment with medroxyprogesterone acetate (MPA) of patients with advanced breast cancer].
    Pieńkowska F; Siedlecki P; Pieńkowski T; Zborzil J; Rubach M
    Nowotwory; 1985; 35(3):243-8. PubMed ID: 2935789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.